[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5):e359-e386.
[2] Torre LA, Bray F, Sieqel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68(6):394-424.
[4] Chattaragada MS, Riganti C, Sassoe M, et al. FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. Oncogene, 2018, 37(6):697-709.
[5] Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0:genes, pathways and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia, 2007, 9(2):166-180.
[6] Tang Z, Li C, Kang B, et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses. Nucl Acids Res, 2017, 45(W1):W98-W102.
[7] Nagy A, Lanczky A, Menyhart O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep, 2018,8(1):9227.
[8] Huang WY, HSU SD, Huang HY, et al. MethHC: a database of DNA methylation and gene expression in human cancer. Nucl Acids Res, 2015,43(D1):D856-D861.
[9] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res, 2019,47(D1):D607-D613.
[10] Chen K, Manga P, Orlow SJ. Pink-eyed dilution protein controls the processing of tyrosinase. Mol Biol Cell, 2002, 13(6):1953-1964.
[11] Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet, 2012, 44(6):694-698.
[12] Mas VR, Maluf DG, Archer KJ, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med, 2009, 15(3-4):85-94.
[13] Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res, 2010, 70(24):10202-10212.
[14] Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology, 2007, 45(4):938-947.
[15] Manieri E, Herrera- Melle L, Mora A, et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med, 2019, 216(5):1108-1119.
[16] Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int, 2010, 18:4(2):439-474.
[17] 王宏伟,季顾惟,张慧,等.保留肝实质肝切除术治疗巴塞罗那A期肝细胞癌的临床疗效及预后因素分析.中华消化外科杂志,2019,18(4):358-367.
[18] 王刚,赵洪波,朱亚玲,等.基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义.实用肝脏病杂志,2019,22(5):724-727.
[19] Long Y, Marian TA, Wei Z. ZFR promotes cell proliferation and tumor development in colorectal and liver cancers. Biochem Biophys Res Commun, 2019, 513(4):1027-1034.
[20] Ezzikouri S, EI Feydi AE, EI Kihal L, et al. Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population. Arch Med Res, 2008, 39(2):236-241.
[21] Yazdani HO, Huang H, Tsung A. Autophagy:dual response in the development of hepatocellular carcinoma. Cells, 2019, 8(2):91.
[22] Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initation and progression. Cold Spring Harb Perspect Med, 2016, 6(3):a026104.
[23] Azer SA. MDM2-p53 interactions in human hepatocellular carcinoma:what is the role of nutlins and new therapeutic options? J Clin Med, 2018, 7(4):64. |